MA55515A - Procédés de traitement de la dystrophie musculaire avec casimersen - Google Patents

Procédés de traitement de la dystrophie musculaire avec casimersen

Info

Publication number
MA55515A
MA55515A MA055515A MA55515A MA55515A MA 55515 A MA55515 A MA 55515A MA 055515 A MA055515 A MA 055515A MA 55515 A MA55515 A MA 55515A MA 55515 A MA55515 A MA 55515A
Authority
MA
Morocco
Prior art keywords
casimersen
methods
muscular dystrophy
treating muscular
treating
Prior art date
Application number
MA055515A
Other languages
English (en)
Inventor
Edward M Kaye
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of MA55515A publication Critical patent/MA55515A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA055515A 2019-03-28 2020-03-25 Procédés de traitement de la dystrophie musculaire avec casimersen MA55515A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825573P 2019-03-28 2019-03-28
US201962902518P 2019-09-19 2019-09-19

Publications (1)

Publication Number Publication Date
MA55515A true MA55515A (fr) 2022-02-09

Family

ID=70286009

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055515A MA55515A (fr) 2019-03-28 2020-03-25 Procédés de traitement de la dystrophie musculaire avec casimersen

Country Status (15)

Country Link
US (1) US20220152086A1 (fr)
EP (1) EP3946376A1 (fr)
JP (1) JP2022526763A (fr)
KR (1) KR20210145192A (fr)
CN (1) CN113660939A (fr)
AU (1) AU2020244803A1 (fr)
BR (1) BR112021018801A2 (fr)
CA (1) CA3134165A1 (fr)
CL (1) CL2021002437A1 (fr)
CO (1) CO2021014024A2 (fr)
IL (1) IL286653A (fr)
MA (1) MA55515A (fr)
MX (1) MX2021011498A (fr)
SG (1) SG11202108757XA (fr)
WO (1) WO2020198268A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021025899A1 (fr) * 2019-08-02 2021-02-11 Sarepta Therapeutics, Inc. Compositions pharmaceutiques à base d'oligomères morpholino phosphorodiamidate
WO2023168427A1 (fr) 2022-03-03 2023-09-07 Yale University Compositions et procédés d'administration de polynucléotides thérapeutiques pour saut d'exon

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
EP0215942B1 (fr) 1985-03-15 1995-07-12 Antivirals Inc. Reactif et procede d'analyse de polynucleotides
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP0786522A2 (fr) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Molécules de RNA enzymatiques pour le traitement de conditions sténotiques
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
WO1999042091A2 (fr) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Compositions d'apport dans des cellules
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
WO2001047496A1 (fr) 1999-12-29 2001-07-05 Mixson A James Copolymere d'histidine et procedes d'utilisation associes
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
JP2018529715A (ja) * 2015-09-30 2018-10-11 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーを処置するための方法
KR20190024977A (ko) * 2016-06-30 2019-03-08 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머
BR112019012651A2 (pt) * 2016-12-19 2020-01-28 Sarepta Therapeutics Inc conjugados de oligômero de salto de éxon para distrofia muscular
EP3687577A1 (fr) * 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Polythérapies pour traiter une dystrophie musculaire

Also Published As

Publication number Publication date
CL2021002437A1 (es) 2022-05-06
SG11202108757XA (en) 2021-10-28
JP2022526763A (ja) 2022-05-26
MX2021011498A (es) 2022-01-04
KR20210145192A (ko) 2021-12-01
AU2020244803A1 (en) 2021-11-18
CA3134165A1 (fr) 2020-10-01
EP3946376A1 (fr) 2022-02-09
US20220152086A1 (en) 2022-05-19
WO2020198268A1 (fr) 2020-10-01
BR112021018801A2 (pt) 2021-11-23
IL286653A (en) 2021-10-31
CO2021014024A2 (es) 2021-10-29
CN113660939A (zh) 2021-11-16

Similar Documents

Publication Publication Date Title
MA50056A (fr) Procédés de traitement de tumeur
MA51103A (fr) Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique
MA45793A (fr) Composés et procédés de stimulation de la myélinisation
MA46427A (fr) Compositions d'oligonucléotides et procédés associés
IL255125A0 (en) Evaluation of complexes of cas9 molecule/guide RNA molecule
MA52003A (fr) Procédés de traitement de maladies associées au hpv
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA46836A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA45426A (fr) Procédés, kits, agents et appareils de transduction
MA47613A (fr) Compositions et procédés de traitement du cancer
MA52789A (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
BR112018005499A2 (pt) métodos de tratamento de pressão intraocular com ativadores de tie-2.
DK3865484T3 (da) Pde9-hæmmer med imidazopyrazinon-rygrad til behandling af perifere sygdomme
MA53506A (fr) Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules
MA46788A (fr) Traitement de la fibrose
MA49508A (fr) Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques
MA40354A (fr) Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
MA47820A (fr) Traitement de la glycogénose de type iii
MA49633A (fr) Agents, utilisations et procédés de traitement
MA52216A (fr) Méthodes de traitement de la colite ulcéreuse
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA43106A (fr) Traitement de l'oligo-ovulation associée à la stéatose hepatique
MA52199A (fr) Compositions et procédés de traitement de la dystrophie maculaire
MA42616A (fr) Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire